Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003

Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use